The surge in demand for angioplasty balloons and stents is
mainly driven by the increasing prevalence of cardiovascular
diseases (CVDs), the growing preference for minimally invasive
procedures, and advancements in drug-coated/drug-eluting balloon
technologies, among other factors. Moreover, the market for
angioplasty balloons and stents is expected to expand due to
numerous ongoing research initiatives, collaborations between
healthcare entities, researchers, and industry stakeholders, as
well as strategic partnerships. These elements are poised to fuel
the growth of the angioplasty balloons and stents market from 2024
to 2030.
LAS VEGAS, May 2, 2024 /PRNewswire/ -- DelveInsight's
Angioplasty Balloons and Stents Market Insights report
provides the current and forecast market analysis, individual
leading angioplasty balloons and stents companies' market shares,
challenges, angioplasty balloons and stents market drivers,
barriers, trends, and key market angioplasty balloons and stents
companies in the market.
Key Takeaways from the Angioplasty Balloons and Stents Market
Report
- As per DelveInsight estimates, North
America is anticipated to dominate the global angioplasty
balloons and stents market during the forecast period.
- Notable angioplasty balloons and stents companies such as B.
Braun SE, BIOTRONIK, Medtronic, Abbott, Boston Scientific
Corporation, Cook, Biosensors International Group, Ltd., MicroPort
Scientific Corporation, Terumo Corporation, Demax Medical
Technology, BD, BrosMed Medical Co., Ltd., Cordis, Sino Medical
Sciences Technology Inc., Concept Medical, and several others,
are currently operating in the angioplasty balloons and stents
market.
- In January 2023, the FDA
approved the Stellarex 0.035" OTW Drug-coated Angioplasty Balloon –
P160049/S015, from Philips Image Guided Therapy Corp.
- In November 2022, Genesis
MedTech Group announced that the FDA has approved the Chocolate
Touch® Drug-coated Balloon PTA Catheter, developed by TriReme
Medical LLC, for the treatment of patients with peripheral artery
disease in the superficial femoral artery and the popliteal
artery.
- In August 2019, B. Braun
Interventional Systems Inc. (BIS) announced that the FDA
granted Breakthrough Device Designation for the SeQuent Please ReX
drug-coated PTCA balloon catheter.
To read more about the latest highlights related to the
angioplasty balloons and stents market, get a snapshot of the key
highlights entailed in the Global Angioplasty Balloons and
Stents Market Report
Angioplasty Balloons and Stents Overview
Angioplasty balloons and stents represent groundbreaking
advancements in cardiovascular medicine, revolutionizing the
treatment of coronary artery disease. Angioplasty balloons are
inflatable catheters used to widen narrowed or blocked arteries by
compressing the plaque against the artery walls, restoring blood
flow to the heart. These balloons are typically inserted into the
affected artery during a minimally invasive procedure known as
percutaneous coronary intervention (PCI). By exerting controlled
pressure, angioplasty balloons effectively alleviate symptoms such
as chest pain and reduce the risk of heart attacks.
Complementing angioplasty balloons, stents are mesh-like tubes
made of metal or polymer that are deployed within the artery
post-balloon inflation to provide structural support and maintain
vessel patency. Stents act as scaffolding, preventing the artery
from collapsing and reducing the likelihood of re-narrowing, a
common complication known as restenosis. Furthermore, drug-eluting
stents release medication over time to inhibit cell proliferation,
further reducing the risk of restenosis. Together, angioplasty
balloons and stents offer a minimally invasive, highly effective
solution for restoring blood flow in diseased coronary arteries,
improving patient outcomes and quality of life.
Angioplasty Balloons and Stents Market Insights
In 2023, North America led the
angioplasty balloons and stents market, driven by increased
utilization of these medical devices in treating peripheral and
coronary artery diseases. This trend stems from rising sedentary
lifestyles, anxiety, and stress, which contribute to conditions
like diabetes and obesity, ultimately elevating the prevalence of
cardiovascular diseases. Factors such as continuous product
launches, regulatory support, and a surge in approvals further
boost the angioplasty balloons and stents market, especially in the
US.
For instance, a 2023 study by the Centre for Disease Control and
Prevention (CDC) revealed that in 2021, 1 in 20 adults aged 20 and
above had coronary artery disease, with coronary heart disease
being the leading cause of death in the US, claiming 375,476 lives
in 2021. Notably, around 2 in 10
CAD-related deaths occurred in adults under 65 years old.
This high disease burden underscores the necessity for drug-eluting
balloons.
Moreover, the American Heart Association estimated that over
500,000 percutaneous coronary intervention (PCI) procedures are
performed annually in the US. The use of drug-coated balloons (DCB)
in PCI procedures has emerged as an innovative approach to dilate
coronary stenosis and administer anti-proliferative drugs to vessel
walls, consequently driving demand for drug-eluting balloons.
Additionally, the presence of major manufacturers, along with
the introduction of new and advanced devices, and favorable
reimbursement policies contribute significantly to the angioplasty
balloons and stents market's growth. For example, in November 2022, Genesis MedTech Group received FDA
approval for the Chocolate Touch® Drug-coated Balloon PTA Catheter,
developed by TriReme Medical LLC, to treat peripheral artery
disease in the superficial femoral artery and the popliteal
artery.
These factors collectively indicate a promising outlook for the
angioplasty balloons and stents market in North America from 2024 to 2030.
To know more about why North
America is leading the market growth in the angioplasty
balloons and stents market, get a snapshot of the Angioplasty
Balloons and Stents Market Outlook
Angioplasty Balloons and Stents Market Dynamics
The angioplasty balloons and stents market dynamics are heavily
influenced by technological advancements, demographic
shifts, and the prevalence of cardiovascular diseases.
As medical technology continues to evolve, angioplasty balloons and
stents have become increasingly sophisticated, offering improved
efficacy and safety profiles. This trend drives angioplasty
balloons and stents market growth as healthcare providers seek
innovative solutions to address the rising burden of
cardiovascular conditions globally.
Moreover, the aging population contributes significantly
to the expansion of the angioplasty balloons and stents market.
With an increasing number of elderly individuals susceptible
to cardiovascular diseases such as coronary artery disease and
peripheral artery disease, the demand for minimally invasive
procedures like angioplasty with stent placement continues to
rise. This demographic shift amplifies the need for advanced
medical devices capable of providing effective treatment while
minimizing patient discomfort and recovery time.
Additionally, regulatory changes and healthcare reforms
play a crucial role in shaping the market dynamics of angioplasty
balloons and stents. Stringent regulations regarding product
safety, efficacy, and reimbursement policies influence the
adoption of new technologies and angioplasty balloons and stents
market entry strategies. Companies operating in this space must
navigate these regulatory landscapes effectively to ensure
compliance and capitalize on emerging opportunities in the
ever-evolving healthcare industry.
Get a sneak peek at the angioplasty balloons and stents market
dynamics @ Angioplasty Balloons and Stents Market Dynamics
Analysis
Report
Metrics
|
Details
|
Coverage
|
Global
|
Study Period
|
2021–2030
|
Angioplasty Balloons
and Stents Market CAGR
|
~4%
|
Key Angioplasty
Balloons and Stents Companies
|
B. Braun SE, BIOTRONIK,
Medtronic, Abbott, Boston Scientific Corporation, Cook, Biosensors
International Group, Ltd., MicroPort Scientific Corporation, Terumo
Corporation, Demax Medical Technology, BD, BrosMed Medical Co.,
Ltd., Cordis, Sino Medical Sciences Technology Inc., Concept
Medical, among others
|
Angioplasty Balloons and Stents Market Assessment
- Angioplasty Balloons and Stents Market Segmentation
-
- Angioplasty Balloons and Stents Market Segmentation By
Product Type: Balloons (Drug-Coated Balloons and Plain Old
Balloons), Stents (Drug-Eluting Stents and Bare Metal Stents)
- Angioplasty Balloons and Stents Market Segmentation By
Indication: Coronary Artery Disease and Peripheral Artery
Disease
- Angioplasty Balloons and Stents Market Segmentation By End
User: Hospitals, Ambulatory Surgical Centers, and Cath Labs
- Angioplasty Balloons and Stents Market Segmentation By
Geography: North America,
Europe, Asia-Pacific, and Rest of World
- Porter's Five Forces Analysis, Product Profiles, Case
Studies, KOL's Views, Analyst's View
Which MedTech key players in the angioplasty balloons and stents
market are set to emerge as the trendsetter explore @
Angioplasty Balloons and Stents Companies
Table of Contents
1
|
Report
Introduction
|
2
|
Executive
summary
|
3
|
Regulatory and Patent
Analysis
|
4
|
Key Factors
Analysis
|
5
|
Porter's Five Forces
Analysis
|
6
|
Angioplasty Balloons
and Stents Market Layout
|
7
|
Global Company Share
Analysis – Key 3-5 Companies
|
8
|
Angioplasty Balloons
and Stents Market Company and
Product Profiles
|
9
|
Project
Approach
|
10
|
About
DelveInsight
|
Interested in knowing the angioplasty balloons and stents market
by 2030? Click to get a snapshot of the Angioplasty
Balloons and Stents Market Trends
Related Reports
Peripheral Arterial Disease Pipeline
Peripheral Arterial Disease Pipeline Insight –
2024 report provides comprehensive insights about the
pipeline landscape, pipeline drug profiles, including clinical and
non-clinical stage products, and the key peripheral arterial
disease companies, including Caladrius Biosciences, Reven
Pharmaceuticals, Inc, Helixmith Co., Ltd, among others.
Peripheral Artery Disease Market
Peripheral Artery Disease Market Insights, Epidemiology, and
Market Forecast – 2032 report deliver an in-depth understanding
of the disease, historical and forecasted epidemiology, as well as
the market trends, market drivers, market barriers, and key
critical limb ischemia companies, including Ixaka Ltd (formerly
Rexgenero), Hemostemix Inc, Lisata Therapeutics, Caladrius
Biosciences, Reven Pharmaceuticals, Inc, Helixmith Co., Ltd,
among others.
Critical Limb Ischemia Pipeline
Critical Limb Ischemia Pipeline Insight –
2024 report provides comprehensive insights about the
pipeline landscape, pipeline drug profiles, including clinical and
non-clinical stage products, and the key critical limb ischemia
companies, including Pluristem Therapeutics, Reven
Pharmaceuticals, Inc., New Beta Innovation Limited, among
others.
Critical Limb Ischemia Market
Critical Limb Ischemia Market Insights, Epidemiology, and
Market Forecast – 2032 report deliver an in-depth understanding
of the disease, historical and forecasted epidemiology, as well as
the market trends, market drivers, market barriers, and key
critical limb ischemia companies, including Boston Scientific
Corporation, AnGes, Inc, Mitsubishi Tanabe Pharma, B. Braun
Melsungen AG, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
https://www.delveinsight.com/medical-devices
Logo:
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/global-angioplasty-balloons-and-stents-market-to-exhibit-substantial-growth-at-a-cagr-of-4-by-2030--delveinsight-302134073.html